Article
Regeneron buys rights to cancer drug Libtayo from Sanofi
Rating:
0.0
Views:
71
Likes:
1
Library:
1
Regeneron Pharmaceuticals said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value